Back to first-pass browser

First-pass extracted concept

mRNA-lipid nanoparticles

Candidate: concept label1 source documents6 linked claims
Jump to explainersJump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Aliases

LNPs, mRNA-LNPs

Extracted Explainers

What the tool is doing

mRNA-LNP formulations package mRNA for vaccine and gene therapy use. The paper studies how their physicochemical stability changes with composition and storage conditions.

Source 1DOIPubMed

Resources required

The abstract describes formulations containing ionizable lipids, PEG-lipids, and Tris buffer, with storage at controlled temperatures. Quality-attribute assays such as particle size, encapsulation, oxidation, and transfection measurements were used.

Source 1DOIPubMed

What problem it solves

These formulations enable mRNA drug products but require stabilization to preserve integrity and effectiveness over time.

Source 1DOIPubMed

What it does not solve

The abstract does not show that all mRNA-LNP formulations are stable under refrigerated or room-temperature storage; instead it reports substantial degradation under those conditions.

Source 1DOIPubMed

Alternatives

The source contrasts different formulation-component choices within mRNA-LNPs, including MC3 versus ALC-0315 ionizable lipids and DMG-PEG2k versus ALC-0159 PEG-lipids.

Source 1DOIPubMed

Evidence Snippets

The long-term stability of mRNA-lipid nanoparticles (LNPs), essential for mRNA vaccines and gene therapies...
Evidence 1Source 1DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1buffer effectsupports2026Source 1DOIPubMed

increasing Tris buffer concentration accelerated 5'-cap hydrolysis in mRNA-LNP formulations.

Quoted textsource-backed
Increasing Tris buffer concentration accelerated 5'-cap hydrolysis, emphasizing the importance of a low-ionic-strength buffer for LNP formulations.
Claim 2design recommendationsupports2026Source 1DOIPubMed

deep-cold storage at or below -20 °C is necessary to preserve mRNA-LNP integrity.

Quoted textsource-backed
Findings re-emphasize the necessity of deep-cold storage (≤-20 °C) and optimized formulation components to preserve mRNA-LNP integrity
Claim 3stability dependencesupports2026Source 1DOIPubMed

mRNA-LNP formulation stability depends on formulation composition and storage temperature.

Quoted textsource-backed
The long-term stability of mRNA-lipid nanoparticles (LNPs)... relies on managing physicochemical properties to preserve their integrity and effectiveness through optimized formulation components... systematically evaluated LNP formulations with varied compositions... stored at -80 °C, -20 °C, 5 °C, and 25 °C
Claim 4storage failuresupports2026Source 1DOIPubMed

storage of mRNA-LNP formulations at 25 °C led to complete loss of transfection within six months.

Quoted textsource-backed
Storage at 25 °C led to complete loss of transfection within six months.
Claim 5storage failuresupports2026Source 1DOIPubMed

storage of mRNA-LNP formulations at 5 °C caused aggregation, reduced in vivo expression, and mRNA degradation.

Quoted textsource-backed
storage at 5 °C caused aggregation, reduced in vivo expression, and mRNA degradation
Claim 6storage outcomesupports2026Source 1DOIPubMed

mRNA-LNP formulations stored at -80 °C and -20 °C retained acceptable stability over the tested period.

Quoted textsource-backed
Formulations stored at -80 °C and -20 °C retained acceptable stability